Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00024167 · ClinicalTrials.gov registry record · Phase 3
Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer
A Phase 3 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 3
- Development phase
- 265
- Enrollment target
NCT00024167: Clinical Trial Phase 3 study, sponsored by M.D. Anderson Cancer Center.
NCT00024167 is a Phase 3 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 265 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00024167, a Phase 3 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 265 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radioactive substances such as strontium-89 may relieve bone pain associated with prostate cancer. It is not yet known whether chemotherapy is more effective with or without strontium-89 in treating bone metastases. PURPOSE: This randomized phase III trial is studying giving chemotherapy together with strontium-89 to see how well it works compared to chemotherapy alone in treating patients with prostate cancer that has spread to the bone.
Interventions
- DRUG Docetaxel
- DRUG Prednisone
- DRUG Doxorubicin hydrochloride
- DRUG Ketoconazole
- DRUG Estramustine phosphate sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 265 participants |
| Start Date | 2002-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00024167
The ClinicalTrials.gov registry entry for NCT00024167 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 265 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Docetaxel is the first listed.
NCT00024167 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00024167 about?
NCT00024167 is a clinical study titled "Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radioactive substances such as strontium-89 may relieve bone pain associated with prostate cancer. It is not yet known whether chemotherapy is more effective with or without stront...
What is the current status of trial NCT00024167?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 265 participants. The study started on 2002-04.
What interventions are being tested in trial NCT00024167?
The interventions under investigation include: Docetaxel (DRUG), Prednisone (DRUG), Doxorubicin hydrochloride (DRUG), Ketoconazole (DRUG), Estramustine phosphate sodium (DRUG).
Who is sponsoring clinical trial NCT00024167?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.